|
1
|
Zardavas D, Fumagalli D and Loi S:
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin
pathway inhibition: A breakthrough in the management of luminal
(ER+/HER2−) breast cancers? Curr Opin Oncol.
24:623–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: Challenges and interventions. Chest.
143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Domvri K, Darwiche K, Zarogoulidis P and
Zarogoulidis K: Following the crumbs: From tissue samples, to
pharmacogenomics, to NSCLC therapy. Transl Lung Cancer Res.
2:256–258. 2013.PubMed/NCBI
|
|
6
|
Ma BB, Hui EP and Mok TS: Population-based
differences in treatment outcome following anticancer drug
therapies. Lancet Oncol. 11:75–84. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vansteenkiste JF, Canon JL, Braud FD,
Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli
C, et al: Safety and efficacy of Buparlisib (BKM120) in patients
with PI3K pathway-activated non-small cell lung cancer: Results
from the Phase II BASALT-1 Study. J Thorac Oncol. 10:1319–1327.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mantripragada K and Khurshid H: Targeting
genomic alterations in squamous cell lung cancer. Front Oncol.
3:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maira SM, Pecchi S, Huang A, Burger M,
Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al:
Identification and characterization of NVP-BKM120, an orally
available pan-class I PI3-kinase inhibitor. Mol Cancer Ther.
11:317–328. 2012. View Article : Google Scholar
|
|
11
|
Gupta P, Das PK and Ukil A:
Antileishmanial effect of 18β-glycyrrhetinic acid is mediated by
Toll-like receptor-dependent canonical and noncanonical p38
activation. Antimicrob Agents Chemother. 59:2531–2539. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heidegger I, Pircher A, Klocker H and
Massoner P: Targeting the insulin-like growth factor network in
cancer therapy. Cancer Biol Ther. 11:701–707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu JA, Li H, Meng X, Fullerton DA,
Nemenoff RA, Mitchell JD and Weyant MJ: Group IIa secretory
phospholipase expression correlates with group IIa secretory
phospholipase inhibition-mediated cell death in K-ras mutant lung
cancer cells. J Thorac Cardiovasc Surg. 144:1479–1485. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Simonetti S, Molina MA, Queralt C, de
Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba
JL, Jimenez U, Isla D, et al: Detection of EGFR mutations with
mutation-specific antibodies in stage IV non-small-cell lung
cancer. J Transl Med. 8:1352010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ware KE, Hinz TK, Kleczko E, Singleton KR,
Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC,
et al: A mechanism of resistance to gefitinib mediated by cellular
reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth
loop. Oncogenesis. 2:e392013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ren H, Chen M, Yue P, Tao H, Owonikoko TK,
Ramalingam SS, Khuri FR and Sun SY: The combination of RAD001 and
NVP-BKM120 synergistically inhibits the growth of lung cancer in
vitro and in vivo. Cancer Lett. 325:139–146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Stiegler AL, Boggon TJ, Kobayashi
S and Halmos B: EGFR-mutated lung cancer: A paradigm of molecular
oncology. Oncotarget. 1:497–514. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roper J, Sinnamon MJ, Coffee EM, Belmont
P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz
ÖH, et al: Combination PI3K/MEK inhibition promotes tumor apoptosis
and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Cancer Lett. 347:204–211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Benjamin D, Colombi M, Moroni C and Hall
MN: Rapamycin passes the torch: A new generation of mTOR
inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slomovitz BM and Coleman RL: The
PI3K/AKT/mTOR pathway as a therapeutic target in endometrial
cancer. Clin Cancer Res. 18:5856–5864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lonetti A, Antunes IL, Chiarini F, Orsini
E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F,
Pession A, et al: Activity of the pan-class I phosphoinositide
3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic
leukemia. Leukemia. 28:1196–1206. 2014. View Article : Google Scholar
|
|
24
|
Bonelli MA, Cavazzoni A, Saccani F,
Alfieri RR, Quaini F, La Monica S, Galetti M, Cretella D, Caffarra
C, Madeddu D, et al: Inhibition of PI3K pathway reduces
invasiveness and epithelial-to-mesenchymal transition in squamous
lung cancer cell lines harboring PIK3CA gene alterations. Mol
Cancer Ther. 14:1916–1927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Diamandis M, White NM and Yousef GM:
Personalized medicine: Marking a new epoch in cancer patient
management. Mol Cancer Res. 8:1175–1187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Antonicelli A, Cafarotti S, Indini A,
Galli A, Russo A, Cesario A, Lococo FM, Russo P, Mainini AF,
Bonifati LG, et al: EGFR-targeted therapy for non-small cell lung
cancer: Focus on EGFR oncogenic mutation. Int J Med Sci.
10:320–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stephen AG, Esposito D, Bagni RK and
McCormick F: Dragging ras back in the ring. Cancer Cell.
25:272–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
